Summary: Apnimed has completed enrollment for its phase 3 SynAIRgy study, which will evaluate the efficacy and safety of its lead candidate AD109, a potential first oral therapy for obstructive sleep apnea (OSA). The trial will focus on adults with mild, moderate, and severe OSA. … [Read more...]
ECU Health Otolaryngologist Completes 100th Inspire Procedure
Summary: Brian Brodish, MD, an otolaryngologist with Eastern Carolina ENT, completed his 100th Inspire therapy procedure at ECU Health Medical Center on July 14. Inspire is an FDA-approved treatment for obstructive sleep apnea (OSA) designed for patients who cannot tolerate CPAP … [Read more...]
Apnimed Completes Enrollment for Phase 3 Sleep Apnea Drug Trial
Summary: Apnimed, a medical-stage pharmaceutical enterprise, has done early enrollment for its LunAIRo stage 3 research, assessing the efficacy and safety of its direct candidate Advert109 for managing obstructive sleep apnea (OSA). Advertisement109, a probable very first oral … [Read more...]